Screener
Apogee Therapeutics, Inc. APGE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDED MARCH 31, 2026 | THREE MONTHS ENDED MARCH 31, 2025 |
|---|---|---|
| Accounts payable | 16 | 1,374 |
| Operating lease liability | (802) | (1,014) |
| Accrued expenses | 4,668 | 2,637 |
| Net cash used in operating activities | (55,570) | (48,477) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (183,244) | (98,201) |
| Maturities of marketable securities | 147,895 | 115,500 |
| Purchases of property and equipment | — | (4,317) |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s operating cash flow?
- Apogee Therapeutics, Inc. (APGE) reported operating cash flow of -$55.57M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Apogee Therapeutics, Inc.'s operating cash flow decreased by 14.6% year-over-year, from -$48.48M to -$55.57M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s operating cash flow has grown at a 74.4% compound annual growth rate (CAGR), from -$74.76M to -$227.45M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Apogee Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude